Presage, Millennium in cancer deal: Presage Biosciences (Seattle, Wash.) partnered with the Millennium Pharmaceuticals Inc. subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to use Presage's technology for preclinical identification of effective drug combinations in solid tumors. Presage will receive upfront fees and research funding, and is eligible for milestones related to identification of successful drug combinations.
"The Presage platform allows to the comparison of multiple drugs in the same tumor within a preclinical model, company officials said, adding the technology has potential for application across the drug development process, from target identification to clinical trial patient selection".
Well, why not? There is nothing wrong with target identification. Just remember one case of patient selection process which has been completely faked at Duke University: video is here.
No comments:
Post a Comment